

www.mesoscale.com®

Ordering Information

MSD Customer Service
 Phone: 1-240-314-2795
 : 1-301-990-2776
 Email: CustomerService@mesoscale.com

Scientific Support

Phone: 1-240-314-2798
 Email: ScientificSupport@mesoscale.com


Company Address

MESO SCALE DISCOVERY®
 A division of
 Meso Scale Diagnostics, LLC.
 1601 Research Boulevard
 Rockville, MD 20850-3173 USA

Product Options	Catalog Number	Description
Multiplex	K15068M, K25068M	U-PLEX Biomarker Group 1 (NHP)
	K156VCK-1/-2/-4	U-PLEX NHP Fractalkine Assay with SECTOR™ plates
Singleplex	K156VCK-21/-22/-24	U-PLEX NHP Fractalkine Assay with QuickPlex® plates
	K256VCK-2/-4	U-PLEX NHP Fractalkine Assay with 384-well plates
Antibody Set	B21VC-2/-3	U-PLEX Human Fractalkine Antibody Set
Assay Protocol	U-PLEX Product Inserts are available at www.mesoscale.com	

The U-PLEX® platform was designed to provide ultimate flexibility for detection of biomarkers in a wide variety of sample types. This datasheet provides the representative performance of the U-PLEX NHP Fractalkine Assay tested on U-PLEX 96-well SECTOR plates run as a multiplex. The data do not represent the product specifications. Under your experimental conditions, the assay may perform differently from the representative data. U-PLEX assays are offered in either singleplex or multiplex; both are available in 96- or 384-well plates. See a U-PLEX product insert for instrument compatibility.

Representative Calibration Curve and Sensitivity



Assay	Median LLOD (pg/mL)	LLOD Range (pg/mL)
Fractalkine	43.1	17.9-107

The Calibrator curve was fitted with a 4-parameter logistic model with a 1/Y² weighting. The lower limit of detection (LLOD) is a calculated concentration corresponding to 2.5X the standard deviations above the background (zero Calibrator).

Precision

	Control	Average Conc. (pg/mL)	Average Intra-run Conc. %CV	Inter-run Conc. %CV
Fractalkine	High	19,800	4.7	10.3
	Mid	8,130	4.1	11.1
	Low	N/A	N/A	N/A

Controls were made by spiking Calibrator into assay diluent at 3 levels within the quantitative range of the assay. Average intra-run concentration %CV is the average %CV of the control replicates within an individual run. Inter-run concentration %CV is the variability of controls across multiple runs. NA = not applicable due to 0% detected

For Research Use Only.
 Not for use in diagnostic procedures.

Spike Recovery

	Spike Level	Serum (N=5)		Plasma (N=5)		Cell Culture Media (N=5)	
		Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range
Cynomolgus Monkey	High	108	26-142	103	68-130	171	99-159
	Mid	101	36-120	100	74-118	156	122-192
	Low	97	58-115	95	85-103	156	118-176
Rhesus Monkey	High	141	114-168	98	66-130	171	99-159
	Mid	118	106-128	100	79-118	156	122-192
	Low	106	99-113	100	92-106	156	118-176

Normal serum, EDTA plasma, and cell culture media were spiked with Calibrator at 3 levels. Undiluted samples were tested to determine the expected concentration of the analyte. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

% Recovery = (measured concentration / expected concentration) x 100

Tested Samples

	Sample Type	Serum (N=10)	Plasma (N=10)	Spiked Serum (N=5)
Cynomolgus Monkey	Median (pg/mL)	5,570	3,780	7,390
	Range (pg/mL)	2,920-20,300	1,550-6,710	5,510-9,790
	% Detected	100	100	100
Rhesus Monkey	Median (pg/mL)	8,800	5,290	10,300
	Range (pg/mL)	3,430-19,500	760-12,300	6,060-14,600
	% Detected	100	100	100

Normal serum and plasma samples were diluted 2-fold prior to the assay.

Dilution Linearity

	Fold Dilution	Serum (N=5)		Plasma (N=5)		Cell Culture Media (N=5)			
		Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range		
Cynomolgus Monkey	2	93	73-125	2	97	90-114	2	84	79-95
	4	99	78-157	4	98	85-135	4	73	66-83
	8	108	69-207	8	96	78-140	8	64	55-72
Rhesus Monkey	2	85	81-90	2	105	90-126	2	84	79-95
	4	79	72-87	4	112	89-143	4	73	66-83
	8	74	67-82	8	113	80-151	8	64	55-72

Normal serum, EDTA plasma, and cell culture media were spiked with Calibrator and tested at different dilutions. Undiluted samples were tested to determine the expected concentration of the analyte. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

% Recovery = (measured concentration / expected concentration) x 100

MSD U-PLEX NHP Fractalkine

Specificity

To assess specificity, the Fractalkine Antibody Set was tested individually against a larger panel of recombinant human analytes for nonspecific binding (CTACK, Eotaxin, Eotaxin-2, Eotaxin-3, ENA-78, FLT3L, Fractalkine, G-CSF, GM-CSF, GRO- α , I-309, IFN- α 2a, IFN- γ , IL-1 α , IL-1 β , IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17AF, IL-17B, IL-17C, IL-17D, IL-17F, IL-18, IL-22, IL-23, IP-10, I-TAC, MCP-1, MCP-2, MCP-3, MCP-4, M-CSF, MDC, MIF, MIP-1 α , MIP-1 β , MIP-3 α , MIP-3 β , MIP-5, SDF-1 α , TARC, TNF- α , TNF- β , TPO, TRAIL, VEGF-A, and YKL-40). Nonspecific binding was less than 0.5%.

% Nonspecificity = (nonspecific signal / specific signal) x 100

Diluent Compatibility

Diluents 57 and 3 are provided with this assay. MSD offers a range of assay and antibody diluents for separate purchase. Depending on your assay needs, other diluents may be tested.

Assay Components

Calibrator: Fractalkine is included in Calibrator 4. The full-length recombinant protein is expressed in a mouse cell line.

Antibodies: The U-PLEX NHP Fractalkine Assay uses a mouse monoclonal antibody for capture and a goat polyclonal antibody for detection.

Assay generation: A

Note: This datasheet contains representative assay performance data. In custom multiplex formats, the assay may perform differently than the representative data shown.

